Patients and the public experienced rapid availability of new vaccines and treatments against COVID-19 infections during the pandemic in 2020. Although it is obvious that this was due to exceptional circumstances, it has raised the expectations for shorter development times for future medicines. Therefore, time pressure on clinical researchers and regulators has further increased and calls for innovation and creativity. In the EUFEMED 2023 conference we will discuss options and strategies for Mastering the New Time Pressure on Human Pharmacology in order to achieve shorter timelines in early medicines development.
Richmond Pharmacology will attend JSCPT 2025 in Tokyo, represented by their leadership team. Topics include early-phase studies, bridging studies between Europe and Asia, gene and RNA-based therapy development, and cross-border collaboration.
By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
.svg){kind=small}
.avif)
